A brief history of the development of antidepressant drugs: From monoamines to glutamate

Experimental and Clinical Psychopharmacology

Volumn 23, Issue 1, 2015, Pages 1-21

  Hillhouse, Todd M ^a,b   Porter, Joseph H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; GLUTAMIC ACID; GLUTAMINE; KETAMINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RAPASTINEL; TRICYCLIC ANTIDEPRESSANT AGENT; VORTIOXETINE; BIOGENIC AMINE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL STUDY; DEPRESSION; HUMAN; MAJOR DEPRESSION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; UNITED STATES; DEPRESSIVE DISORDER, MAJOR; PHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DEPRESSIVE DISORDER, MAJOR; GLUTAMIC ACID; HUMANS;

EID: 84925625537     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0038550     Document Type: Article

References (182)

1. aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry, 67, 139-145. http://dx.doi.org/10.1016/j .biopsych.2009.08.038
2. Alam, M. Y., Jacobsen, P. L., Chen, Y., Serenko, M., & Mahableshwarkar, A. R. (2014). Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: Results of an open-label, flexible-dose, 52-week extension study. International Clinical Psychopharmacology, 29, 36-44.
3. Altamura, C. A., Mauri, M. C., Ferrara, A., Moro, A. R., D'Andrea, G., & Zamberlan, F. (1993). Plasma and platelet excitatory amino acids in psychiatric disorders. The American Journal of Psychiatry, 150, 1731-1733.
4. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
5. Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000). Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry, 47, 305-313. http://dx.doi.org/10.1016/S0006-3223(99)00159-6
6. Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P. F., . . . Monteggia, L. M. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 475, 91-95. http://dx.doi.org/10.1038/nature10130
7. Azbill, R. D., Mu, X., & Springer, J. E. (2000). Riluzole increases highaffinity glutamate uptake in rat spinal cord synaptosomes. Brain Research, 871, 175-180. http://dx.doi.org/10.1016/S0006-8993(00)02430-6
8. Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., . . . Stensbøl, T. B. (2011). Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. Journal of Medicinal Chemistry, 54, 3206-3221. http://dx.doi.org/10.1021/jm101459g
9. Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007). Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology, 32, 1888-1902. http://dx.doi.org/10.1038/sj.npp.1301312
10. Beneyto, M., & Meador-Woodruff, J. H. (2008). Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology, 33, 2175-2186. http://dx.doi.org/10.1038/sj.npp .1301604
11. Berk, M., Plein, H., & Ferreira, D. (2001). Platelet glutamate receptor supersensitivity in major depressive disorder. Clinical Neuropharmacology, 24, 129-132. http://dx.doi.org/10.1097/00002826-200105000-00002
12. Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47, 351-354. http://dx.doi.org/10.1016/S0006-3223(99)00230-9
13. Berman, R. M., Sanacora, G., Anand, A., Roach, L. M., Fasula, M. K., Finkelstein, C. O., . . . Charney, D. S. (2002). Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry, 51, 469-473. http://dx.doi.org/10.1016/S0006-3223(01)01285-9
14. Bernard, R., Kerman, I. A., Thompson, R. C., Jones, E. G., Bunney, W. E., Barchas, J. D., . . . Watson, S. J. (2011). Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Molecular Psychiatry, 16, 634-646. http://dx .doi.org/10.1038/mp.2010.44
15. Billett, E. E. (2004). Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology, 25(1-2), 139-148. http://dx.doi.org/10.1016/S0161-813X(03)00094-9
16. Birnbaum, H. G., Kessler, R. C., Kelley, D., Ben-Hamadi, R., Joish, V. N., & Greenberg, P. E. (2010). Employer burden of mild, moderate, and severe major depressive disorder: Mental health services utilization and costs, and work performance. Depression and Anxiety, 27, 78-89. http://dx.doi.org/10.1002/da.20580
17. Block, W., Träber, F., von Widdern, O., Metten, M., Schild, H., Maier, W., . . . Jessen, F. (2009). Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: Correlates and predictors of treatment response. The International Journal of Neuropsychopharmacology, 12, 415-422. http://dx.doi.org/10.1017/S1461145708009516
18. Boulenger, J.-P., Loft, H., & Florea, I. (2012). A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. Journal of Psychopharmacology, 26, 1408-1416. http://dx.doi.org/10.1177/0269881112441866
19. Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014). Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: A randomized, doubleblind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. International Clinical Psychopharmacology, 29, 138-149. http://dx.doi.org/10.1097/YIC.0000000000000018
20. Bresink, I., Danysz, W., Parsons, C. G., & Mutschler, E. (1995). Different binding affinities of NMDA receptor channel blockers in various brain regions-Indication of NMDA receptor heterogeneity. Neuropharmacology, 34, 533-540. http://dx.doi.org/10.1016/0028-3908(95)00017-Z
21. Browne, C. A., & Lucki, I. (2013). Antidepressant effects of ketamine: Mechanisms underlying fast-acting novel antidepressants. Frontiers in Pharmacology, 4, 161. http://dx.doi.org/10.3389/fphar.2013.00161
22. Bunney, W. E., Jr., & Davis, J. M. (1965). Norepinephrine in depressive reactions. A review. Archives of General Psychiatry, 13, 483-494. http://dx.doi.org/10.1001/archpsyc.1965.01730060001001
23. Burgdorf, J., Zhang, X. L., Nicholson, K. L., Balster, R. L., Leander, J. D., Stanton, P. K., . . . Moskal, J. R. (2013). GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology, 38, 729-742. http://dx.doi.org/10.1038/npp.2012.246
24. Butler, T. W., Blake, J. F., Bordner, J., Butler, P., Chenard, B. L., Collins, M. A., . . . Zhao, D. (1998). (3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: A conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol. Journal of Medicinal Chemistry, 41, 1172-1184. http://dx.doi.org/10.1021/jm9707986
25. Bymaster, F. P., Dreshfield-Ahmad, L. J., Threlkeld, P. G., Shaw, J. L., Thompson, L., Nelson, D. L., . . . Wong, D. T. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 25, 871-880. http://dx.doi.org/10.1016/S0893-133X(01)00298-6
26. Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., . . . Perry, K. W. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27, 699-711. http://dx.doi.org/10.1016/S0893-133X(02)00346-9
27. Campbell, I. C., Marangos, P. J., Parma, A., Garrick, N. A., & Murphy, D. L. (1982). Localization of monoamine oxidases A and B in primate brains relative to neuron-specific and non-neuronal enolases. Neurochemical Research, 7, 657-666. http://dx.doi.org/10.1007/BF00965519
28. Chandley, M. J., Szebeni, A., Szebeni, K., Crawford, J. D., Stockmeier, C. A., Turecki, G., . . . Ordway, G. A. (2014). Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression. The International Journal of Neuropsychopharmacology, 17, 1569-1578. http://dx.doi.org/10.1017/S1461145714000662
29. Charney, D. S. (1998). Monoamine dysfunction and the pathophysiology and treatment of depression. The Journal of Clinical Psychiatry, 59(Suppl 14), 11-14.
30. Chen, T.-Y., & Tzeng, N.-S. (2013). Aripiprazole: A dopamine modulator that mimics methylphenidate in producing faster antidepressant effects. Medical Hypotheses, 81, 183-185. http://dx.doi.org/10.1016/j.mehy .2013.05.009
31. Chilukuri, H., Reddy, N. P., Pathapati, R. M., Manu, A. N., Jollu, S., & Shaik, A. B. (2014). Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian Journal of Psychological Medicine, 36, 71-76. http://dx.doi.org/10.4103/0253-7176.127258
32. Choudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., . . . Jones, E. G. (2005). Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. PNAS Proceedings of the National Academy of Sciences of the United States of America, 102, 15653-15658. http://dx.doi.org/10.1073/pnas .0507901102
33. Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., . . . Metz, A. (2002). Prevalence of sexual dysfunction among newer antidepressants. The Journal of Clinical Psychiatry, 63, 357-366. http://dx.doi.org/10.4088/JCP.v63n0414
34. Cusack, B., Nelson, A., & Richelson, E. (1994). Binding of antidepressants to human brain receptors: Focus on newer generation compounds. Psychopharmacology, 114, 559-565. http://dx.doi.org/10.1007/BF02244985
35. Delgado, P. L. (2000). Depression: The case for a monoamine deficiency. The Journal of Clinical Psychiatry, 61(Suppl. 6), 7-11.
36. Delgado, P. L., Price, L. H., Miller, H. L., Salomon, R. M., Aghajanian, G. K., Heninger, G. R., & Charney, D. S. (1994). Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Archives of General Psychiatry, 51, 865-874. http://dx.doi.org/10.1001/archpsyc.1994.03950110025005
37. Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., . . . Zarate, C. A., Jr. (2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry, 67, 793-802. http://dx.doi .org/10.1001/archgenpsychiatry.2010.90
38. Domino, E. F. (1999). History of modern psychopharmacology: A personal view with an emphasis on antidepressants. Psychosomatic Medicine, 61, 591-598. http://dx.doi.org/10.1097/00006842-199909000-00002
39. Domino, E. F. (2010). Taming the ketamine tiger. 1965. Anesthesiology, 113, 678-684.
40. Drug Enforcement Administration. (2013). Ketamine. Springfield, VA: U. S. Department of Justice, Drug Enforcement Administration.
41. du Jardin, K. G., Jensen, J. B., Sanchez, C., & Pehrson, A. L. (2014). Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. European Neuropsychopharmacology, 24, 160-171. http://dx.doi.org/10.1016/j .euroneuro.2013.07.001
42. Duncan, W. C. J., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., . . . Zarate, C. A. J. (2013). Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. The International Journal of Neuropsychopharmacology, 16, 301-311. http://dx.doi.org/10.1017/S1461145712000545
43. Fagius, J., Osterman, P. O., Sidén, A., & Wiholm, B.-E. (1985). Guillaim-Barré syndrome following zimeldine treatment. Journal of Neurology, Neurosurgery, and Psychiatry, 48, 65-69. http://dx.doi.org/10.1136/jnnp.48.1.65
44. Fangmann, P., Assion, H.-J., Juckel, G., González, C. A., & López-Muñoz, F. (2008). Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: Tricyclics and tetracyclics. Journal of Clinical Psychopharmacology, 28, 1-4. http://dx.doi.org/10.1097/jcp .0b013e3181627b60
45. Fava, M. (2003). Diagnosis and definition of treatment-resistant depression. Biological Psychiatry, 53, 649-659. http://dx.doi.org/10.1016/S0006-3223(03)00231-2
46. Fava, M., & Davidson, K. G. (1996). Definition and epidemiology of treatment-resistant depression. The Psychiatric Clinics of North America, 19, 179-200. http://dx.doi.org/10.1016/S0193-953X(05)70283-5
47. Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005). 15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Primary Care Companion to the Journal of Clinical Psychiatry, 7, 106-113. http://dx .doi.org/10.4088/PCC.v07n0305
48. Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., . . . Kupfer, D. J., & the for the STAR_D Investigators Group. (2003). Background and rationale for the sequenced treatment alternatives to relieve depression (STAR_D) study. The Psychiatric Clinics of North America, 26, 457-494, x. http://dx.doi.org/10.1016/S0193-953X(02)00107-7
49. Feighner, J., Hendrickson, G., Miller, L., & Stern, W. (1986). Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. Journal of Clinical Psychopharmacology, 6, 27-32. http://dx.doi.org/10.1097/00004714-198602000-00006
50. Feighner, J. P., Meredith, C. H., Stern, W. C., Hendrickson, G., & Miller, L. L. (1984). A double-blind study of bupropion and placebo in depression. The American Journal of Psychiatry, 141, 525-529.
51. Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009). Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 33, 70-75. http://dx.doi .org/10.1016/j.pnpbp.2008.10.005
52. Fox, H. H., & Gibas, J. T. (1953). Synthetic tuberculostats. VII monoalkyl derivatives of isonicotinylhydrazine. The Journal of Organic Chemistry, 18, 994-1002. http://dx.doi.org/10.1021/jo50014a014
53. Garakani, A., Martinez, J. M., Yehuda, R., & Gorman, J. M. (2013). Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. Journal of Affective Disorders, 146, 262-265. http://dx.doi.org/10.1016/j.jad.2012.06.037
54. Ghasemi, M., Kazemi, M. H., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2014). Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Research, 215, 355-361. http://dx.doi.org/10.1016/j.psychres.2013.12.008
55. Gibb, A., & Deeks, E. D. (2014). Vortioxetine: First global approval. Drugs, 74, 135-145. http://dx.doi.org/10.1007/s40265-013-0161-9
56. Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003). The economic burden of depression in the United States: How did it change between 1990 and 2000? The Journal of Clinical Psychiatry, 64, 1465-1475. http://dx.doi.org/10.4088/JCP.v64n1211
57. Haile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., . . . Mathew, S. J. (2014). Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatmentresistant depression. The International Journal of Neuropsychopharmacology, 17, 331-336. http://dx.doi.org/10.1017/S1461145713001119
58. Hashimoto, K., Sawa, A., & Iyo, M. (2007). Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry, 62, 1310-1316. http://dx.doi.org/10.1016/j.biopsych.2007.03.017
59. Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007). Reduced prefrontal glutamate/glutamine and _-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Archives of General Psychiatry, 64, 193-200. http://dx.doi.org/10.1001/archpsyc.64.2.193
60. Heninger, G. R., Delgado, P. L., & Charney, D. S. (1996). The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry, 29, 2-11. http://dx.doi.org/10.1055/s-2007-979535
61. Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013). A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. The International Journal of Neuropsychopharmacology, 16, 501-506. http://dx.doi.org/10.1017/S1461145712000910
62. Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006). Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. Journal of Affective Disorders, 93(1-3), 239-243. http://dx.doi.org/10.1016/j.jad .2006.03.004
63. Hirota, K., Hashimoto, Y., & Lambert, D. G. (2002). Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. Anesthesia and Analgesia, 95, 1607-1610. http://dx.doi.org/10.1097/00000539-200212000-00025
64. Hirschfeld, R. M. A. (2000). History and evolution of the monoamine hypothesis of depression. The Journal of Clinical Psychiatry, 61(Suppl. 6), 4-6.
65. Holly, E. N., LaCrosse, A. L., & Hillhouse, T. M. (2014). Review of Group I and Group II metabotropic glutamate receptors, and their role in the pathophysiology of major depressive disorder. In O. M. Foster (Ed.), Metabotropic Glutamate Receptors: Molecular Mechanisms, Role in Neurological Disorders, and Pharmacological Effects (pp. 135-150). Hauppauge, NY: Nova Science Publishers.
66. Ibrahim, L., Diazgranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., . . . Zarate, C. A., Jr. (2012). Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: Results from a 4-week, double-blind, placebocontrolled study. Neuropsychopharmacology, 37, 1526-1533. http://dx .doi.org/10.1038/npp.2011.338
67. Ibrahim, L., Diaz Granados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., . . . Zarate, C. A., Jr. (2012). A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychopharmacology, 32, 551-557. http://dx.doi.org/10.1097/JCP.0b013e31825d70d6
68. Irwin, S. A., & Iglewicz, A. (2010). Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. Journal of Palliative Medicine, 13, 903-908. http://dx.doi.org/10.1089/jpm.2010.9808
69. Irwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013). Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: A 28-day open-label proof-of-concept trial. Journal of Palliative Medicine, 16, 958-965. http://dx.doi.org/10.1089/jpm.2012.0617
70. Jensen, J. B., du Jardin, K. G., Song, D., Budac, D., Smagin, G., Sanchez, C., & Pehrson, A. L. (2014). Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: Evidence for direct 5-HT receptor modulation. European Neuropsychopharmacology, 24, 148-159. http://dx.doi.org/10.1016/j .euroneuro.2013.10.011
71. Jordan, S., Chen, R., Fernalld, R., Johnson, J., Regardie, K., Kambayashi, J., . . . Kikuchi, T. (2006). In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors. European Journal of Pharmacology, 540, 53-56. http://dx.doi.org/10.1016/j.ejphar .2006.04.026
72. Kapur, S., & Seeman, P. (2002). NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Molecular Psychiatry, 7, 837-844. http://dx.doi.org/10.1038/sj.mp.4001093
73. Karolewicz, B., Stockmeier, C. A., & Ordway, G. A. (2005). Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology, 30, 1557-1567. http://dx.doi .org/10.1038/sj.npp.1300781
74. Karolewicz, B., Szebeni, K., Gilmore, T., Maciag, D., Stockmeier, C. A., & Ordway, G. A. (2009). Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. The International Journal of Neuropsychopharmacology, 12, 143-153. http://dx.doi.org/10.1017/S1461145708008985
75. Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., . . . Wang, P. S., & the National Comorbidity Survey Replication. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association, 289, 3095-3105. http://dx.doi.org/10.1001/jama.289.23.3095
76. Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H.-U. (2012). Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International Journal of Methods in Psychiatric Research, 21, 169-184. http://dx.doi.org/10.1002/mpr.1359
77. Kew, J. N., & Kemp, J. A. (2005). Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology, 179, 4-29. http://dx.doi.org/10.1007/s00213-005-2200-z
78. Kirshner, N. (1962). Uptake of catecholamines by a particulate fraction of the adrenal medulla. The Journal of Biological Chemistry, 237, 2311-2317.
79. Kuhn, R. (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry, 115, 459-464.
80. Küçükibrahimoğlu, E., Saygi{dotless}n, M. Z., Calişkan, M., Kaplan, O. K.,Ünsal, C., & Gören, M. Z. (2009). The change in plasma GABA, glutamine and glutamate levels in fluoxetine-or S-citalopram-treated female patients with major depression. European Journal of Clinical Pharmacology, 65, 571-577. http://dx.doi.org/10.1007/s00228-009-0650-7
81. Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., . . . Zarate, C., Jr. (2012). Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biological Psychiatry, 72, e27-e28. http://dx.doi.org/10.1016/j.biopsych.2012.05.031
82. Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. (2014). Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Translational Psychiatry, 4, e469. http://dx.doi.org/10.1038/tp.2014.105
83. Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., . . . Murrough, J. W. (2014). A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry, 76, 970-976. http://dx.doi.org/10.1016/j .biopsych.2014.03.026
84. Lara, D. R., Bisol, L. W., & Munari, L. R. (2013). Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. The International Journal of Neuropsychopharmacology, 16, 2111-2117. http://dx.doi .org/10.1017/S1461145713000485
85. Lee, S., Jeong, J., Kwak, Y., & Park, S. K. (2010). Depression research: Where are we now? Molecular Brain, 3, 8. http://dx.doi.org/10.1186/1756-6606-3-8
86. Lenze, E. J., Skidmore, E. R., Begley, A. E., Newcomer, J. W., Butters, M. A., & Whyte, E. M. (2012). Memantine for late-life depression and apathy after a disabling medical event: A 12-week, double-blind placebo-controlled pilot study. International Journal of Geriatric Psychiatry, 27, 974-980. http://dx.doi.org/10.1002/gps.2813
87. Letchworth, S. R., Smith, H. R., Porrino, L. J., Bennett, B. A., Davies, H. M. L., Sexton, T., & Childers, S. R. (2000). Characterization of a tropane radioligand, [(3)H]2_-propanoyl-3_-(4-tolyl) tropane ([(3)H]PTT), for dopamine transport sites in rat brain. The Journal of Pharmacology and Experimental Therapeutics, 293, 686-696.
88. Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R. J., & Pettegrew, J. W. (2000). Increased cerebrospinal fluid glutamine levels in depressed patients. Biological Psychiatry, 47, 586-593. http://dx.doi .org/10.1016/S0006-3223(99)00284-X
89. Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., . . . Duman, R. S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329, 959-964. http://dx.doi.org/10.1126/science.1190287
90. Loomer, H. P., Saunders, J. C., & Kline, N. S. (1957). A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatric Research Reports, 8, 129-141.
91. López-Muñoz, F., Alamo, C., Juckel, G., & Assion, H. J. (2007). Half a century of antidepressant drugs: On the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: Monoamine oxidase inhibitors. Journal of Clinical Psychopharmacology, 27, 555-559. http://dx.doi.org/10.1097/jcp.0b013e3181bb617
92. Lord, B., Wintmolders, C., Langlois, X., Nguyen, L., Lovenberg, T., & Bonaventure, P. (2013). Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus. European Journal of Phamacology, 715, 21-25. http://dx .doi.org/10.1016/j.ejphar.2013.06.028
93. Lotufo-Neto, F., Trivedi, M., & Thase, M. E. (1999). Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology, 20, 226-247. http://dx.doi.org/10.1016/S0893-133X(98)00075-X
94. Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., . . . Zarate, C. A., Jr. (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders, 159, 56-61. http://dx.doi.org/10.1016/j.jad.2014.02.017
95. Machado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009). The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. The Neuroscientist, 15, 525-539. http://dx.doi.org/10.1177/1073858409336093
96. Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A., Jr. (2009). Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. The Journal of Clinical Psychiatry, 70, 1662-1666. http://dx.doi.org/10.4088/JCP.08m04659
97. Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A., & Scharpé, S. (1998). Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: Modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatrica Scandinavica, 97(Suppl.), 302-308. http://dx.doi.org/10.1111/j.1600-0447.1998.tb10004.x
98. Marsden, W. N. (2011). Stressor-induced NMDAR dysfunction as a unifying hypothesis for the aetiology, pathogenesis and comorbidity of clinical depression. Medical Hypotheses, 77, 508-528. http://dx.doi.org/10.1016/j.mehy.2011.06.021
99. Mathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., & Charney, D. S. (2010). Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial. The International Journal of Neuropsychopharmacology, 13, 71-82. http://dx.doi.org/10.1017/S1461145709000169
100. Mathews, D. C., Henter, I. D., & Zarate, C. A. J. (2012). Targeting the glutamatergic system to treat major depressive disorder: Rationale and progress to date. Drugs, 72, 1313-1333.
101. Mauri, M. C., Ferrara, A., Boscati, L., Bravin, S., Zamberlan, F., Alecci, M., & Invernizzi, G. (1998). Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology, 37, 124-129. http://dx.doi.org/10.1159/000026491
102. McCambridge, J., Winstock, A., Hunt, N., & Mitcheson, L. (2007). 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. European Addiction Research, 13, 57-64. http://dx.doi.org/10.1159/000095816
103. McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014). A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. The International Journal of Neuropsychopharmacology, 17, 1557-1567. http://dx.doi.org/10.1017/S1461145714000546
104. McNulty, J. P., & Hahn, K. (2012). Compounded oral ketamine. International Journal of Pharmaceutical Compounding, 16, 364-368.
105. Mendelsohn, L. G., Kalra, V., Johnson, B. G., & Kerchner, G. A. (1985). Sigma opioid receptor: Characterization and co-identity with the phencyclidine receptor. The Journal of Pharmacology and Experimental Therapeutics, 233, 597-602.
106. Michael, N., Erfurth, A., Ohrmann, P., Arolt, V., Heindel, W., & Pfleiderer, B. (2003). Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychological Medicine, 33, 1277-1284. http://dx.doi.org/10.1017/S0033291703007931
107. Millan, M. J., Gobert, A., Lejeune, F., Newman-Tancredi, A., Rivet, J.-M., Auclair, A., & Peglion, J.-L. (2001). S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. The Journal of Pharmacology and Experimental Therapeutics, 298, 565-580.
108. Mirza, Y., Tang, J., Russell, A., Banerjee, S. P., Bhandari, R., Ivey, J., . . . Rosenberg, D. R. (2004). Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 341-348. http://dx.doi.org/10.1097/00004583-200403000-00017
109. Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., . . . Wainer, I. W. (2014). D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology. Epub ahead of print. http://dx.doi.org/10.1007/s00213-014-3669-0
110. Montgomery, S. A., Gabriel, R., James, D., Hawley, C., & Burkitt, P. (1989). The specificity of the zimelidine reaction. International Clinical Psychopharmacology, 4, 19-23. http://dx.doi.org/10.1097/00004850-198901000-00003
111. Moreira, R. (2011). The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clinical Drug Investigation, 31(Suppl. 1), 5-17. http://dx.doi.org/10.2165/1159616-S0-000000000-00000
112. Mørk, A., Montezinho, L. P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., . . . Sanchez, C. (2013). Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacology, Biochemistry, and Behavior, 105, 41-50. http://dx.doi.org/10.1016/j.pbb .2013.01.019
113. Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., . . . Stensbøl, T. B. (2012). Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder. The Journal of Pharmacology and Experimental Therapeutics, 340, 666-675. http://dx.doi.org/10.1124/jpet.111.189068
114. Moskal, J. R., Burch, R., Burgdorf, J. S., Kroes, R. A., Stanton, P. K., Disterhoft, J. F., & Leander, J. D. (2014). GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opinion on Investigational Drugs, 23, 243-254. http://dx.doi.org/10.1517/13543784.2014.852536
115. Moskal, J. R., Kuo, A. G., Weiss, C., Wood, P. L., O'Connor Hanson, A., Kelso, S., . . . Disterhoft, J. F. (2005). GLYX-13: A monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology, 49, 1077-1087. http://dx.doi.org/10.1016/j.neuropharm.2005.06.006
116. Mount, C., & Downton, C. (2006). Alzheimer disease: Progress or profit? Nature Medicine, 12, 780-784. http://dx.doi.org/10.1038/nm0706-780
117. Muhonen, L. H., Lönnqvist, J., Juva, K., & Alho, H. (2008). Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. The Journal of Clinical Psychiatry, 69, 392-399. http://dx.doi.org/10.4088/JCP.v69n0308
118. Muller, J. C., Pryor, W. W., Gibbons, J. E., & Orgain, E. S. (1955). Depression and anxiety occurring during Rauwolfia therapy. Journal of the American Medical Association, 159, 836-839. http://dx.doi.org/10.1001/jama.1955.02960260006002
119. Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., . . . Mathew, S. J. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. The American Journal of Psychiatry, 170, 1134-1142. http://dx.doi.org/10.1176/appi.ajp.2013.13030392
120. Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., . . . Iosifescu, D. V. (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatmentresistant major depression. Biological Psychiatry, 74, 250-256. http://dx.doi.org/10.1016/j.biopsych.2012.06.022
121. Murrough, J. W., Wan, L.-B., Iacoviello, B., Collins, K. A., Solon, C., Glicksberg, B., . . . Burdick, K. E. (2013). Neurocognitive effects of ketamine in treatment-resistant major depression: Association with antidepressant response. Psychopharmacology, 231, 481-488. http://dx .doi.org/10.1007/s00213-013-3255-x
122. National Institute of Mental Health's Psychoactive Drug Screening Program. (2014). Contract # HHSN-271-2013-00017-C (NIMH PDSP). Available from http://pdsp.med.unc.edu/
123. Naurex Inc. (2014). Naurex reports positive top-line phase 2b results for novel antidepressant GLYX-13 and advances NRX-1074 into phase 2 depression study. Retrieved from http://naurex.com/wp-content/uploads/2014/05/Naurex_Clinical_Advances-2014.05.06.pdf
124. Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., . . . Zarate, C. A., Jr. (2014). Clinical predictors of ketamine response in treatment-resistant major depression. Journal of Clinical Psychiatry, 75, e417-e423. http://dx.doi.org/10.4088/JCP.13m08698
125. Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Richards, E. M., Vande Voort, J. L., Ballard, E. D., . . . Zarate, C. A., Jr. (2014). Riluzole likely lacks antidepressant efficacy in ketamine non-responders. [Advance online publication]. Journal of Psychiatric Research, 58, 197-199. http://dx.doi.org/10.1016/j.jpsychires.2014.07.022
126. Nilsson, B. S. (1983). Adverse reactions in connection with zimeldine treatment-A review. Acta Psychiatrica Scandinavica, 68(Suppl.), 115-119. http://dx.doi.org/10.1111/j.1600-0447.1983.tb11110.x
127. Nishimura, M., Sato, K., Okada, T., Yoshiya, I., Schloss, P., Shimada, S., & Tohyama, M. (1998). Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology, 88, 768-774. http://dx.doi.org/10.1097/00000542-199803000-00029
128. Nudmamud-Thanoi, S., & Reynolds, G. P. (2004). The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neuroscience Letters, 372, 173-177. http://dx.doi.org/10.1016/j.neulet.2004.09.035
129. Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997). Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. The Journal of Pharmacology and Experimental Therapeutics, 283, 1305-1322.
130. Palucha, A., & Pilc, A. (2005). The involvement of glutamate in the pathology of depression. Drug News Perspective, 18, 262-268. http://dx.doi.org/10.1358/dmp.2005.18.4.908661
131. Papakostas, G. I. (2008). Tolerability of modern antidepressants. Journal of Clinical Psychiatry, 69(Suppl. E1), 8-13.
132. Papakostas, G. I. (2009). Serotonin norepinephrine reuptake inhibitors: Spectrum of efficacy in major depressive disorder. Primary Psychiatry, 16(Suppl. 4), 16-24.
133. Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry, 62, 1217-1227. http://dx.doi.org/10.1016/j.biopsych.2007.03.027
134. Pearce, E. F., & Murphy, J. A. (2014). Vortioxetine for the treatment of depression. The Annals of Pharmacotherapy, 48, 758-765. http://dx.doi .org/10.1177/1060028014528305
135. Pfleiderer, B., Michael, N., Erfurth, A., Ohrmann, P., Hohmann, U., Wolgast, M., . . . Heindel, W. (2003). Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Research: Neuroimaging, 122, 185-192. http://dx.doi.org/10.1016/S0925-4927(03)00003-9
136. Pin, J. P., & Duvoisin, R. (1995). The metabotropic glutamate receptors: Structure and functions. Neuropharmacology, 34, 1-26. http://dx.doi .org/10.1016/0028-3908(94)00129-G
137. Pletscher, A. (1991). The discovery of antidepressants: A winding path. Experientia, 47, 4-8. http://dx.doi.org/10.1007/bf02041242
138. Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology, 28, 631-637. http://dx.doi.org/10.1097/JCP.0b013e31818a6cea
139. Price, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., . . . Mathew, S. J. (2014). Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depression and Anxiety, 31, 335-343. http://dx.doi.org/10.1002/da.22253
140. Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry, 66, 522-526. http://dx.doi.org/10.1016/j.biopsych.2009.04.029
141. Pristupa, Z. B., Wilson, J. M., Hoffman, B. J., Kish, S. J., & Niznik, H. B. (1994). Pharmacological heterogeneity of the cloned and native human dopamine transporter: Disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Molecular Pharmacology, 45, 125-135.
142. Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., . . . Frye, M. A. (2013). Serial infusions of low-dose ketamine for major depression. Journal of Psychopharmacology, 27, 444-450. http://dx.doi.org/10.1177/0269881113478283
143. Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X.-P., Setola, V., Treble, R., & Iversen, L. (2013). The ketamine analogue methoxetamine and 3-and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS ONE, 8, e59334. http://dx.doi.org/10.1371/journal.pone.0059334
144. Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse, 39, 32-41. http://dx.doi .org/10.1002/1098-2396(20010101)39:132::AID-SYN53.0.CO;2-3
145. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., . . . Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR_D report. The American Journal of Psychiatry, 163, 1905-1917. http://dx.doi.org/10.1176/appi.ajp.163.11.1905
146. Salomon, R. M., Miller, H. L., Krystal, J. H., Heninger, G. R., & Charney, D. S. (1997). Lack of behavioral effects of monoamine depletion in healthy subjects. Biological Psychiatry, 41, 58-64. http://dx.doi.org/10.1016/0006-3223(95)00670-2
147. Sanacora, G., Gueorguieva, R., Epperson, C. N., Wu, Y.-T., Appel, M., Rothman, D. L., . . . Mason, G. F. (2004). Subtype-specific alterations of _-aminobutyric acid and glutamate in patients with major depression. Archives of General Psychiatry, 61, 705-713. http://dx.doi.org/10.1001/archpsyc.61.7.705
148. Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., & Krystal, J. H. (2007). Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Bio-logical Psychiatry, 61, 822-825. http://dx.doi.org/10.1016/j.biopsych .2006.08.037
149. Sanacora, G., Smith, M. A., Pathak, S., Su, H. L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2013). Lanicemine: A low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Molecular Psychiatry, 19, 1-8.
150. Sánchez, C., & Hyttel, J. (1999). Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cellular and Molecular Neurobiology, 19, 467-489. http://dx.doi.org/10.1023/A:1006986824213
151. Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. The American Journal of Psychiatry, 122, 509-522.
152. Schulberg, H. C., Katon, W., Simon, G. E., & Rush, A. J. (1998). Treating major depression in primary care practice: An update of the Agency for Health Care Policy and Research Practice Guidelines. Archives of General Psychiatry, 55, 1121-1127. http://dx.doi.org/10.1001/archpsyc.55.12.1121
153. Seeman, P., Ko, F., & Tallerico, T. (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Molecular Psychiatry, 10, 877-883. http://dx.doi.org/10.1038/sj.mp.4001682
154. Shaw, D. M., Camps, F. E., & Eccleston, E. G. (1967). 5-Hydroxytryptamine in the hind-brain of depressive suicides. The British Journal of Psychiatry, 113, 1407-1411. http://dx.doi.org/10.1192/bjp.113.505.1407
155. Shek, D. T. L. (2007). Tackling adolescent substance abuse in Hong Kong: Where we should and should not go. The Scientific World Journal, 7, 2021-2030. http://dx.doi.org/10.1100/tsw.2007.315
156. Shiroma, P. R., Albott, C. S., Johns, B., Thuras, P., Wels, J., & Lim, K. O. (2014). Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. The International Journal of Neuropsychopharmacology, 17, 1805-1813. http://dx.doi .org/10.1017/S1461145714001011
157. Shore, P. A., Pletscher, A., Tomich, E. G., Carlsson, A., Kuntzman, R., & Brodie, B. B. (1957). Role of brain serotonin in reserpine action. Annals of the New York Academy of Sciences, 66, 609-615. http://dx.doi.org/10.1111/j.1749-6632.1957.tb40751.x
158. Shore, P. A., Silver, S. L., & Brodie, B. B. (1955). Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science, 122, 284-285. http://dx.doi.org/10.1126/science.122.3163.284-a
159. Shulman, K. I., Herrmann, N., & Walker, S. E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs, 27, 789-797. http://dx.doi.org/10.1007/s40263-013-0097-3
160. Smith, D. J., Bouchal, R. L., deSanctis, C. A., Monroe, P. J., Amedro, J. B., Perrotti, J. M., & Crisp, T. (1987). Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology, 26, 1253-1260. http://dx.doi.org/10.1016/0028-3908(87)90084-0
161. Smith, E. G., Deligiannidis, K. M., Ulbricht, C. M., Landolin, C. S., Patel, J. K., & Rothschild, A. J. (2013). Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: A randomized, doubleblind, placebo-controlled trial. Journal of Clinical Psychiatry, 74, 966-973. http://dx.doi.org/10.4088/JCP.12m08252
162. Stahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005). SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectrums, 10, 732-747.
163. Stahl, S. M., Pradko, J. F., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004). A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Primary Care Companion to the Journal of Clinical Psychiatry, 6, 159-166. http://dx.doi.org/10.4088/PCC.v06n0403
164. Substance Abuse and Mental Health Services Administration. (2013). Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration.
165. Thomas, D. R., Nelson, D. R., & Johnson, A. M. (1987). Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology, 93, 193-200. http://dx.doi.org/10.1007/BF00179933
166. Uher, R., Mors, O., Rietschel, M., Rajewska-Rager, A., Petrovic, A., Zobel, A., . . . McGuffin, P. (2011). Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: A secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. Journal of Clinical Psychiatry, 72, 1478-1484. http://dx.doi.org/10.4088/JCP.10m06419
167. Vaishnavi, S. N., Nemeroff, C. B., Plott, S. J., Rao, S. G., Kranzler, J., & Owens, M. J. (2004). Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biological Psychiatry, 55, 320-322. http://dx.doi.org/10.1016/j.biopsych.2003.07.006
168. Valentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., . . . Sanacora, G. (2011). The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Research: Neuroimaging, 191, 122-127. http://dx.doi.org/10.1016/j.pscychresns.2010.10.009
169. Wang, S. J., Wang, K. Y., & Wang, W. C. (2004). Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience, 125, 191-201. http://dx.doi .org/10.1016/j.neuroscience.2004.01.019
170. Weiner, N., Cloutier, G., Bjur, R., & Pfeffer, R. I. (1972). Modification of norepinephrine synthesis in intact tissue dy drugs and during short-term adrenergic nerve stimulation. Pharmacological Reviews, 24, 203-221.
171. Winstock, A. R., Mitcheson, L., Gillatt, D. A., & Cottrell, A. M. (2012). The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU International, 110, 1762-1766. http://dx.doi .org/10.1111/j.1464-410X.2012.11028.x
172. Wong, D. T., Bymaster, F. P., & Engleman, E. A. (1995). Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sciences, 57, 411-441. http://dx.doi.org/10.1016/0024-3205(95)00209-O
173. Wong, D. T., Bymaster, F. P., Horng, J. S., & Molloy, B. B. (1975). A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine. The Journal of Pharmacology and Experimental Therapeutics, 193, 804-811.
174. Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., & Molloy, B. B. (1974). A selective inhibitor of serotonin uptake: Lilly 110140, 3-(ptrifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sciences, 15, 471-479. http://dx.doi.org/10.1016/0024-3205(74)90345-2
175. Wong, D. T., Perry, K. W., & Bymaster, F. P. (2005). Case history: The discovery of fluoxetine hydrochloride (Prozac). Nature Reviews Drug Discovery, 4, 764-774.
176. Yamakura, T., Mori, H., Masaki, H., Shimoji, K., & Mishina, M. (1993). Different sensitivities of NMDA receptor channel subtypes to noncompetitive antagonists. Neuroreport, 4, 687-690. http://dx.doi.org/10.1097/00001756-199306000-00021
177. Yamakura, T., & Shimoji, K. (1999). Subunit-and site-specific pharmacology of the NMDA receptor channel. Progress in Neurobiology, 59, 279-298. http://dx.doi.org/10.1016/S0301-0082(99)00007-6
178. Zarate, C. A., Jr., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., . . . Luckenbaugh, D. A. (2013). A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biological Psychiatry, 74, 257-264. http://dx.doi.org/10.1016/j.biopsych.2012.10.019
179. Zarate, C. A., Jr., Payne, J. L., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., . . . Manji, H. K. (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. The American Journal of Psychiatry, 161, 171-174. http://dx.doi.org/10.1176/appi.ajp .161.1.171
180. Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., . . . Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63, 856-864. http://dx.doi.org/10.1001/archpsyc.63.8.856
181. Zarate, C. A., Jr., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., . . . Charney, D. S. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. The American Journal of Psychiatry, 163, 153-155. http://dx .doi.org/10.1176/appi.ajp.163.1.153
182. Zigman, D., & Blier, P. (2013). Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: A case report. Journal of Clinical Psychopharmacology, 33, 270-272. http://dx.doi.org/10.1097/JCP.0b013e3182856865